How Many Platelets Do You Need in PRP? Why Platelet Concentration Matters
- 2 days ago
- 6 min read
By Dr. Jeffrey Peng, MD · Published March 6, 2025 · 8 min read
Watch the Full Video
If you are considering a platelet rich plasma injection, one of the most important questions you can ask your provider is: how many platelets will be in my PRP? Research increasingly shows that platelet count is one of the strongest predictors of treatment success — and not all PRP preparations deliver an adequate dose.
A growing body of evidence suggests that achieving at least 5 to 10 billion platelets per injection is critical for meaningful, sustained improvement in conditions like knee osteoarthritis. Understanding why platelet concentration matters can help you make a more informed decision and get the best possible results from your treatment.
Does PRP Work for Knee Arthritis?
Over the past several years, the evidence supporting PRP for knee osteoarthritis has grown substantially. A recent systematic review and meta-analysis of 21 level-one randomized controlled trials concluded that PRP improves pain and function in patients with knee osteoarthritis for up to 12 months and is superior to hyaluronic acid injections, regardless of leukocyte concentration or number of injections.
However, not every PRP study reports positive results. When a trial shows no benefit, the question is whether PRP genuinely failed — or whether the preparation simply did not contain enough platelets to produce a therapeutic effect. The answer often lies in platelet dosing.
What Did the RESTORE Trial Get Wrong?
The RESTORE trial, published in JAMA in 2021, is one of the most widely cited studies reporting negative results for PRP. After 12 months of follow-up, the investigators found that PRP did not result in significant improvement in symptoms or joint structure compared to saline placebo injections for knee osteoarthritis.
The RESTORE trial was well-designed and well-conducted. However, it had a critical flaw from the outset: the PRP preparation kit used in the study yielded approximately 1 billion platelets per injection. This is the equivalent of prescribing a subtherapeutic dose of medication. If a patient with high blood pressure receives 10 milligrams of a drug when the therapeutic dose is 100 milligrams, the medication will appear ineffective — but the problem is not the drug itself. It is the dose.
This is exactly what happened in the RESTORE trial. The platelet dose was far too low to produce a meaningful clinical response, and the study's conclusions must be interpreted in that context.
Why 10 Billion Platelets May Be the Target
A landmark study by Bansal et al. (2021) directly addressed the dose question. The researchers randomized 150 patients with knee osteoarthritis to receive either a single PRP injection containing approximately 10 billion platelets or a single hyaluronic acid injection. Patients were followed at 1, 3, 6, and 12 months.
The protocol involved drawing 50 cc of blood and concentrating it down to 8 cc of PRP. No activating agent was used. The control group received Monovisc, a high molecular weight hyaluronic acid preparation commonly used in the United States.
At one month, both groups showed significant improvements in pain and function. However, after the first month, the hyaluronic acid group steadily declined and returned to baseline by six months. In contrast, the PRP group maintained significantly better scores all the way through 12 months of follow-up. The study concluded that an absolute count of 10 billion platelets is crucial for sustained chondroprotective effects in moderate knee osteoarthritis.
This represents ten times the platelet dose used in the RESTORE trial — a difference that likely explains the dramatically different outcomes between the two studies.
What Is the Ideal Platelet Count for PRP?
While 10 billion platelets appears to be an excellent target, other studies have demonstrated meaningful benefits at somewhat lower doses. A randomized trial comparing PRP to hyaluronic acid for hip arthritis found that PRP provided longer-lasting improvements in pain, function, and daily activities at six months, with approximately 7 billion platelets per injection.
Perhaps most compelling are studies comparing PRP head-to-head against stem cell therapies. Zaffagnini et al. (2022) compared a single PRP injection to a single injection of microfragmented adipose tissue (fat-derived stem cells) for knee osteoarthritis. Their PRP preparation contained approximately 21 billion platelets. The results showed that PRP was equivalent to stem cell treatment out to 24 months of follow-up.
Similarly, Anz et al. (2022) compared a single PRP injection to a single treatment of bone marrow aspirate concentrate for knee arthritis. Their PRP contained approximately 9 billion platelets, and once again, PRP was found to be equivalent to stem cell therapy through 24 months.
These findings suggest that when PRP contains an adequate platelet dose — generally in the range of 7 to 10 billion or more — it can produce results that rival much more expensive and invasive stem cell treatments.
Why Do Some Providers Recommend Multiple PRP Injections?
Many earlier PRP studies used protocols involving two or three injections spaced several weeks apart. A randomized, double-blind, placebo-controlled trial by Lin et al. (2019) found that three PRP injections produced clinically significant improvements for up to one year and outperformed both hyaluronic acid and saline placebo. However, the kit used in that study yielded only about 1 to 2 billion platelets per injection.
Three injections at that dose would deliver roughly 3 to 6 billion total platelets over the course of treatment — still less than a single injection from a newer preparation that yields 7 to 10 billion platelets. In my practice, I prefer to use systems that concentrate a higher number of platelets from a larger blood draw, which allows patients to achieve therapeutic platelet counts in a single treatment session rather than requiring multiple office visits.
What Should You Ask Before Getting PRP?
Before scheduling a PRP injection, there are several critical questions to ask your provider. First, find out how many platelets will be in your final PRP product. Based on the current evidence, you want to target a minimum of 5 to 10 billion platelets for large joint injections such as the knee or hip.
Second, ask what PRP preparation kit your provider uses. Different systems produce vastly different platelet yields. Some older or lower-cost kits process only a small blood draw and recover a fraction of available platelets, resulting in a subtherapeutic dose.
If your provider cannot answer these questions, consider seeking a specialist who is more experienced in the field of orthobiologics and regenerative medicine. PRP treatments are still relatively new, and the quality of the preparation varies enormously between clinics.
How Long Does High Dose PRP Last?
When PRP is administered at an adequate platelet dose, studies consistently show symptom improvement lasting 12 months or longer. In the Bansal et al. study, PRP with 10 billion platelets maintained superior outcomes compared to hyaluronic acid through the full year of follow-up.
However, it is important to set realistic expectations. At one year, approximately 38% of patients in the PRP group required retreatment as symptoms began to return toward baseline. This was still significantly better than the 53% retreatment rate in the control group. These results are consistent with what previous trials have shown, and this is why many providers — including myself — recommend considering repeat PRP treatment at around the one-year mark.
The science of PRP is evolving rapidly. As preparation techniques improve and our understanding of optimal dosing deepens, outcomes will continue to get better. If you are considering PRP for knee or hip arthritis, the most important step you can take is ensuring your provider uses a high-yield system that delivers an adequate platelet count. To learn more about how PRP fits into a broader treatment plan, visit our PRP information page or schedule a consultation.
References
1. Bansal H, Leon J, Pont JL, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Sci Rep. 2021;11(1):3971. doi:10.1038/s41598-021-83025-2
2. Kim JH, Park YB, Ha CW. Are leukocyte-poor or multiple injections of platelet-rich plasma more effective than hyaluronic acid for knee osteoarthritis? A systematic review and meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2022;143(7):3879-3897. doi:10.1007/s00402-022-04637-5
3. Bennell KL, Paterson KL, Metcalf BR, et al. Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: The RESTORE randomized clinical trial. JAMA. 2021;326(20):2021-2030. doi:10.1001/jama.2021.19415
4. Nouri F, Babaee M, Peydayesh P, Esmaily H, Raeissadat SA. Comparison between the effects of ultrasound guided intra-articular injections of platelet-rich plasma (PRP), high molecular weight hyaluronic acid, and their combination in hip osteoarthritis: a randomized clinical trial. BMC Musculoskelet Disord. 2022;23(1):856. doi:10.1186/s12891-022-05787-8
5. Zaffagnini S, Andriolo L, Boffa A, et al. Microfragmented adipose tissue versus platelet-rich plasma for the treatment of knee osteoarthritis: A prospective randomized controlled trial at 2-year follow-up. Am J Sports Med. 2022;50(11):2881-2892. doi:10.1177/03635465221115821
6. Anz AW, Plummer HA, Cohen A, Everts PA, Andrews JR, Hackel JG. Bone marrow aspirate concentrate is equivalent to platelet-rich plasma for the treatment of knee osteoarthritis at 2 years: A prospective randomized trial. Am J Sports Med. 2022;50(3):618-629. doi:10.1177/03635465211072554
7. Lin KY, Yang CC, Hsu CJ, Yeh ML, Renn JH. Intra-articular injection of platelet-rich plasma is superior to hyaluronic acid or saline solution in the treatment of mild to moderate knee osteoarthritis: A randomized, double-blind, triple-parallel, placebo-controlled clinical trial. Arthroscopy. 2019;35(1):106-117. doi:10.1016/j.arthro.2018.06.035
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments